News

The FDA has accepted AstraZeneca and MedImmune’s biologics license application (BLA) for moxetumomab pasudotox, which is an investigational anti-CD22 recombinant immunotoxin and potential new medicine to treat adult

ALKS 5461 is a proprietary, investigational, once-daily oral medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an

DFN-02 is an intranasal spray formulation made up of sumatriptan 10mg and Aegis Therapeutics’ permeation-enhancing technology Intravail. The drug had shown its ability to treat pain and associated

MAVERICK-HCM is the first clinical trial of mavacamten in non-obstructive HCM, expanding its potential use to an additional sub-type of HCM beyond the obstructed form of the disease.

A pre-specified interim analysis, conducted by an independent Data Safety Monitoring Board (DSMB) of the efficacy and safety data for the study in an overall population of 275

As per terms of the deal, MedImmune will exclusively develop bi-specific and multi-specific antibody products derived from a Compugen pipeline program. The exclusive license will allow MedImmune to

The preliminary safety data showed that tafamidis was generally well tolerated in this population and no new safety signals were identified. The ATTR-ACT study was designed to assess

The approval is for patients whose minimal residual disease (MRD) is greater than or equal to 0.1 percent. This indication is approved under accelerated approval based on MRD

The company said it will stop trial based on significant positive results from interim analysis. According to the company, the MN-001 significantly reduced mean serum triglycerides, which is a